Scholar Rock Holding (SRRK) Liabilities and Shareholders Equity (2017 - 2026)

Scholar Rock Holding (SRRK) posted quarterly Liabilities and Shareholders Equity of $535.3 million for Q1 2026, up 31.33% year-over-year from $407.6 million in Q1 2025, and up 32.4% quarter-over-quarter from $404.3 million in Q4 2025.

Scholar Rock Holding (SRRK) Liabilities and Shareholders Equity (2017 - 2026) Analysis & Trends

Scholar Rock Holding's Liabilities and Shareholders Equity history runs 10 years deep, the most recent figure standing at $535.3 million for Q1 2026.

  • In Q1 2026, Liabilities and Shareholders Equity rose 31.33% year-over-year to $535.3 million; the TTM figure through Mar 2026 stood at $1.7 billion (up 31.26% YoY), while the FY2025 annual figure was $404.3 million, down 14.88% from the prior year.
  • Liabilities and Shareholders Equity for Q1 2026 stood at $535.3 million, up from $404.3 million in the prior quarter.
  • The five-year high for Liabilities and Shareholders Equity was $535.3 million in Q1 2026, with the low at $179.1 million in Q3 2024.
  • The 5-year median for Liabilities and Shareholders Equity is $340.0 million (2025), against an average of $343.9 million.
  • The sharpest annual moves came in 2023 and 2025: Liabilities and Shareholders Equity slumped 35.77% in 2023, then jumped 129.84% in 2025.
  • Scholar Rock Holding's Liabilities and Shareholders Equity stood at $358.2 million in 2022, then decreased by 13.16% to $311.0 million in 2023, then soared by 52.69% to $474.9 million in 2024, then decreased by 14.88% to $404.3 million in 2025, then jumped by 32.4% to $535.3 million in 2026.
  • Business Quant data shows SRRK's Liabilities and Shareholders Equity at $535.3 million in Q1 2026, $404.3 million in Q4 2025, and $411.7 million in Q3 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Liabilities and Shareholders Equity (Qtr)
1 Vertex Pharmaceuticals 128.13 Bn 120.28 Bn 2.84 Bn 27.42 Bn
2 Regeneron Pharmaceuticals 112.33 Bn 104.33 Bn 3.93 Bn 41.73 Bn
3 Argenx Se 53.24 Bn 48.05 Bn 1.41 Bn 10.03 Bn
4 Revolution Medicines 43.64 Bn 43.64 Bn - 4.32 Bn
5 BeOne Medicines 39.27 Bn 34.17 Bn 1.53 Bn 9.18 Bn
6 MindWalk Holdings 35.32 Bn 35.31 Bn 1.82 Bn 15.59 Mn
7 Royalty Pharma 33.72 Bn 35.84 Bn - 19.82 Bn
8 Alnylam Pharmaceuticals 30.58 Bn 27.27 Bn 992.69 Mn 5.56 Bn
9 Insmed 27.01 Bn 25.85 Bn 358.27 Mn 2.10 Bn
10 Scholar Rock Holding 6.39 Bn 6.39 Bn - 523.54 Mn

Historic Data

Download Data
DateValue
Jun 30, 2026 523.54 Mn
Mar 31, 2026 535.25 Mn
Dec 31, 2025 404.27 Mn
Sep 30, 2025 411.72 Mn
Jun 30, 2025 340.05 Mn
Mar 31, 2025 407.55 Mn
Dec 31, 2024 474.92 Mn
Sep 30, 2024 179.13 Mn
Jun 30, 2024 226.87 Mn
Mar 31, 2024 267.29 Mn
Dec 31, 2023 311.04 Mn
Sep 30, 2023 250.69 Mn
Jun 30, 2023 284.90 Mn
Mar 31, 2023 314.72 Mn
Dec 31, 2022 358.17 Mn
Sep 30, 2022 390.30 Mn
Jun 30, 2022 424.13 Mn
Mar 31, 2022 265.98 Mn
Dec 31, 2021 304.45 Mn
Sep 30, 2021 298.39 Mn